These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 19579092)

  • 1. Antecedents and correlates of methadone treatment entry: a comparison of out-of-treatment and in-treatment cohorts.
    Schwartz RP; Kelly SM; O'Grady KE; Mitchell SG; Brown BS
    Drug Alcohol Depend; 2011 May; 115(1-2):23-9. PubMed ID: 21126830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interim methadone treatment: impact on arrests.
    Schwartz RP; Jaffe JH; O'Grady KE; Kinlock TW; Gordon MS; Kelly SM; Wilson ME; Ahmed A
    Drug Alcohol Depend; 2009 Aug; 103(3):148-54. PubMed ID: 19443133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of opiate agonist maintenance therapy on drug use within social networks of injecting drug users.
    Lloyd JJ; Strathdee SA; Pu M; Havens JR; Cornelius LJ; Huettner S; Latkin CA
    Am J Addict; 2008; 17(5):414-21. PubMed ID: 18770085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors associated with illegal drug use among older methadone clients.
    Rosen D
    Gerontologist; 2004 Aug; 44(4):543-7. PubMed ID: 15331811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of drug treatment re-entry following relapse to cocaine use in DATOS.
    Grella CE; Hser YI; Hsieh SC
    J Subst Abuse Treat; 2003 Oct; 25(3):145-54. PubMed ID: 14670520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlates of stimulant treatment outcome across treatment modalities.
    Peirce JM; Petry NM; Roll JM; Kolodner K; Krasnansky J; Stabile PQ; Brown C; Stitzer ML
    Am J Drug Alcohol Abuse; 2009; 35(1):48-53. PubMed ID: 19152207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opiate-dependent patients on a waiting list for methadone maintenance treatment are at high risk for mortality until treatment entry.
    Peles E; Schreiber S; Adelson M
    J Addict Med; 2013; 7(3):177-82. PubMed ID: 23519049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent modifications to the US methadone treatment system are a Band-Aid-not a solution-to the nation's broken opioid use disorder treatment system.
    Krawczyk N; Joudrey PJ; Simon R; Russel DM; Frank D
    Health Aff Sch; 2023 Jul; 1(1):qxad018. PubMed ID: 38756842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Within-subject evaluation of interim buprenorphine treatment during waitlist delays.
    Oleskowicz TN; Ochalek TA; Peck KR; Badger GJ; Sigmon SC
    Drug Alcohol Depend; 2021 Mar; 220():108532. PubMed ID: 33508690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bridging waitlist delays with interim buprenorphine treatment: initial feasibility.
    Sigmon SC; C Meyer A; Hruska B; Ochalek T; Rose G; Badger GJ; Brooklyn JR; Heil SH; Higgins ST; Moore BA; Schwartz RP
    Addict Behav; 2015 Dec; 51():136-42. PubMed ID: 26256469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interim treatment: Bridging delays to opioid treatment access.
    Sigmon SC
    Prev Med; 2015 Nov; 80():32-6. PubMed ID: 25937593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient perspectives on choosing buprenorphine over methadone in an urban, equal-access system.
    Gryczynski J; Jaffe JH; Schwartz RP; DuĊĦek KA; Gugsa N; Monroe CL; O'Grady KE; Olsen YK; Mitchell SG
    Am J Addict; 2013; 22(3):285-91. PubMed ID: 23617873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Buprenorphine for human immunodeficiency virus/hepatitis C virus-coinfected patients: does it serve as a bridge to hepatitis C virus therapy?
    Taylor LE; Maynard MA; Friedmann PD; Macleod CJ; Rich JD; Flanigan TP; Sylvestre DL
    J Addict Med; 2012 Sep; 6(3):179-85. PubMed ID: 22614935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dropout from interim methadone and subsequent comprehensive methadone maintenance.
    Gryczysnki J; Schwartz R; O'Grady K; Jaffe J
    Am J Drug Alcohol Abuse; 2009 Dec; 35(6):394-398. PubMed ID: 22053122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A business case for quality improvement in addiction treatment: evidence from the NIATx collaborative.
    Quanbeck AR; Madden L; Edmundson E; Ford JH; McConnell KJ; McCarty D; Gustafson DH
    J Behav Health Serv Res; 2012 Jan; 39(1):91-100. PubMed ID: 21918924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns in admission delays to outpatient methadone treatment in the United States.
    Gryczynski J; Schwartz RP; Salkever DS; Mitchell SG; Jaffe JH
    J Subst Abuse Treat; 2011 Dec; 41(4):431-9. PubMed ID: 21821378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment entry among individuals on a waiting list for methadone maintenance.
    Gryczynski J; Schwartz R; O'Grady K; Jaffe J
    Am J Drug Alcohol Abuse; 2009; 35(5):290-4. PubMed ID: 19579092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized controlled trial of interim methadone maintenance.
    Schwartz RP; Highfield DA; Jaffe JH; Brady JV; Butler CB; Rouse CO; Callaman JM; O'Grady KE; Battjes RJ
    Arch Gen Psychiatry; 2006 Jan; 63(1):102-9. PubMed ID: 16389204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incarcerated intravenous heroin users: predictors of post-release utilization of methadone maintenance treatment.
    Lin HC; Wang PW; Yang YH; Tsai JJ; Yen CF
    J Addict Dis; 2016; 35(2):109-18. PubMed ID: 26670167
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.